# OnCo record ntrk-fusion-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/ntrk-fusion-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "ntrk-fusion-nsclc" ;
  schema:name "NTRK fusion-positive non-small-cell lung cancer"@en ;
  schema:alternateName "NTRK-rearranged lung cancer"@en, "TRK fusion lung cancer"@en, "NTRK1, NTRK2 or NTRK3 fusion NSCLC"@en ;
  schema:description "NTRK fusion lung cancer is very rare and is treated with the same TRK-blocking pills approved for any cancer with the fusion: larotrectinib, entrectinib or repotrectinib shrink most tumours, including in the brain, so the point is to test broadly enough to find it."@en ;
  schema:url <https://onco.cc/cancers/ntrk-fusion-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trk_receptor> ;
  schema:citation <https://en.wikipedia.org/wiki/Trk_receptor>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/ros1/> ;
  onco:drugs <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/repotrectinib/> ;
  onco:companies <https://onco.cc/companies/bayer/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/bms/> ;
  onco:pathways <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:terms <https://onco.cc/terms/gene-fusion/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/gatekeeper-mutation/>, <https://onco.cc/terms/brain-metastases/> ;
  onco:trials <https://onco.cc/trials/navigate/>, <https://onco.cc/trials/nct02568267/>, <https://onco.cc/trials/nct03093116/> ;
  onco:people <https://onco.cc/people/alexander-drilon/> ;
  onco:pipeline <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/trials/nct03093116/> ;
  onco:standardOfCare <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/trials/navigate/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/trials/nct02568267/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/> .